Immune surveillance in clinical regression of pre-invasive squamous cell lung cancer
- Pennycuick, A; Teixeira, VH; AbdulJabbar, K; Raza, SEA; Lund, T; Akarca, AU; Rosenthal, R; Kalinke, L; Chandrasekharan, DP; Pipinikas, CP; Lee-Six, H; Hynds, RE; Gowers, KHC; Henry, JY; Millar, FR; Hagos, YB; Denais, C; Falzon, M; Moore, DA; Antoniou, S; Durrenberger, PF; Furness, AJS; Carroll, B; Marceaux, C; Asselin-Labat, ML; Larson, W; Betts, C; Coussens, LM; Thakrar, RM; George, J; Swanton, C; Thirlwell, C; Campbell, PJ; Marafioti, T; Yuan, Y; Quezada, SA; McGranahan, N; Janes, SM;
Publication Year 2020-07-20, Volume 10, Issue #10, Page 1489-99
- Journal Title
- Cancer Discovery
- Publication Type
- Journal Article
- Before squamous cell lung cancer develops, pre-cancerous lesions can be found in the airways. From longitudinal monitoring, we know that only half of such lesions become cancer, whereas a third spontaneously regress. While recent studies have described the presence of an active immune response in high-grade lesions, the mechanisms underpinning clinical regression of pre-cancerous lesions remain unknown. Here, we show that host immune surveillance is strongly implicated in lesion regression. Using bronchoscopic biopsies from human subjects, we find that regressive carcinoma in-situ lesions harbour more infiltrating immune cells than those that progress to cancer. Moreover, molecular profiling of these lesions identifies potential immune escape mechanisms specifically in those that progress to cancer: antigen presentation is impaired by genomic and epigenetic changes, CCL27/CCR10 signalling is upregulated, and the immunomodulator TNFSF9 is downregulated. Changes appear intrinsic to the CIS lesions as the adjacent stroma of progressive and regressive lesions are transcriptomically similar.
- WEHI Research Division(s)
- Personalised Oncology
- PubMed ID
- Publisher's Version
- Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2020-08-05 10:02:58Last Modified: 2020-10-17 02:44:55